Leerink Partnrs Has Positive Estimate for COGT Q2 Earnings

Cogent Biosciences, Inc. (NASDAQ:COGT) – Analysts at Leerink Partnrs increased their Q2 2025 earnings per share (EPS) estimates for shares of Cogent Biosciences in a research report issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the technology company will post earnings per share of ($0.63) for the quarter, up from their prior estimate of ($0.64). The consensus estimate for Cogent Biosciences’ current full-year earnings is ($2.42) per share. Leerink Partnrs also issued estimates for Cogent Biosciences’ Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.57) EPS and FY2027 earnings at $1.13 EPS.

Several other research firms also recently commented on COGT. Wedbush reissued a “neutral” rating and issued a $11.00 target price on shares of Cogent Biosciences in a report on Tuesday, February 25th. Piper Sandler raised Cogent Biosciences to a “strong-buy” rating in a report on Friday, March 7th. HC Wainwright dropped their target price on Cogent Biosciences from $17.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. Robert W. Baird dropped their target price on Cogent Biosciences from $8.00 to $7.00 and set a “neutral” rating on the stock in a report on Wednesday, May 7th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cogent Biosciences in a research note on Wednesday, February 26th. Three research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $14.29.

Cogent Biosciences Trading Down 2.7%

Cogent Biosciences stock opened at $4.99 on Monday. The business’s fifty day simple moving average is $5.55 and its two-hundred day simple moving average is $7.64. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.61. The company has a market capitalization of $568.14 million, a price-to-earnings ratio of -2.01 and a beta of 1.91.

Cogent Biosciences (NASDAQ:COGT) last released its earnings results on Tuesday, May 6th. The technology company reported ($0.52) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.04.

Institutional Investors Weigh In On Cogent Biosciences

Several institutional investors have recently modified their holdings of COGT. CWM LLC boosted its position in shares of Cogent Biosciences by 11,869.9% during the first quarter. CWM LLC now owns 8,738 shares of the technology company’s stock valued at $52,000 after buying an additional 8,665 shares during the last quarter. Schonfeld Strategic Advisors LLC purchased a new stake in shares of Cogent Biosciences during the fourth quarter valued at $78,000. Hsbc Holdings PLC purchased a new stake in shares of Cogent Biosciences during the fourth quarter valued at $81,000. KLP Kapitalforvaltning AS bought a new position in Cogent Biosciences in the fourth quarter valued at about $88,000. Finally, E Fund Management Co. Ltd. purchased a new position in Cogent Biosciences in the fourth quarter worth about $89,000.

Cogent Biosciences Company Profile

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.